Detrusor sphincter dyssynergia

Summary

Detrusor sphincter dyssynergia (MONDO:0001447) is a disease. A subtype of urinary bladder disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	detrusor sphincter dyssynergia
Mondo ID	MONDO:0001447
DOID	DOID:12145
SNOMED CT	236655005
UMLS	C0341747
MedGen	574618
Is cancer (heuristic)	no

Also known as: detrusor sphincter dyssynergia · detrusor sphincter dyssynergia (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of urinary bladder disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › detrusor sphincter dyssynergia

Related subtypes (16): low compliance bladder, female stress incontinence, urinary bladder tuberculosis, urinary bladder neoplasm, urinary schistosomiasis, vesicoureteral reflux, cystitis, overactive bladder, bladder calculus, bladder neck obstruction, postcholecystectomy syndrome, ureterolithiasis, bladder diverticulum, ureterocele, Hinman syndrome, disorder of neck of urinary bladder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.